上海辉启生物医药科技

Huiqi Bio is a Shanghai-based biotechnology company specializing in the discovery and development of innovative small molecule drugs, with a particular focus on covalent inhibitors and targeted protein degradation (TPD). The company leverages its proprietary platform to address historically "undruggable" targets in oncology and immunology, aiming to provide next-generation therapies for patients with high unmet medical needs. Its research efforts are centered on high-value targets such as KRAS mutations, including G12D and G12V, which are prevalent in various solid tumors. Supported by top-tier venture capital firms like Qiming Venture Partners and Sequoia China, Huiqi Bio is advancing a robust pipeline of precision medicines toward clinical validation.